• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1.5 Contact Hour(s)

    Release Date

    Friday, March 15, 2019

    Offline Date

    Sunday, March 15, 2020

    ACPE Expiration Date

    Saturday, February 19, 2022

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      Venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease.  The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Since 2009 four DOACs have been FDA approved for these indications, and their use is wide-spread, it is challenging to ensure patient safety as each agent has slightly different pharmacokinetic considerations with its use. Certain clinical situations may favor one DOAC over another. This program will focus on the prevention and treatment of venous thromboembolism (VTE) and address safety and efficacy with each agent, initial recommendations for dosing and adjustments based on renal considerations, drug interactions, and age and weight. Common risk factors for bleeding will be identified as well as options in support of the management of bleeding, if it should occur, are proposed.

      Handouts

      • Slide Document :   19006H01_6pp.pdf
      • Slide Document :   19006H01_2pp.pdf

      Financial Support By

      Bristol-Myers Squibb and Pfizer Alliance
    • Pharmacist

      Assess the need for anticoagulation therapy for prevention of VTE.
      Choose an anticoagulation treatment plan for VTE based on patient specific factors and special considerations to improve patient outcomes.
      Compare and contrast the indications, advantages and potential adverse effects of direct oral anticoagulants for the treatment of VTE.

      Nurse

      Choose an anticoagulation treatment plan for VTE based on patient specific factors and special considerations to improve patient outcomes.
      Compare and contrast the indications, advantages and potential adverse effects of direct oral anticoagulants for the treatment of VTE.
      Assess the need for anticoagulation therapy for prevention of VTE.
    • Activity Type

      Knowledge

      CE Broker

      20-644337

      Universal Activity Number

      Pharmacist 0798-0000-19-006-H01-P
      Nurse 0798-0000-19-006-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).